Alinity, a family of next-generation clinical chemistry and immunoassay diagnostics from Abbott Laboratories (NYSE:ABT) is now being offered in Europe and other countries that distinguish the CE mark.
As global healthcare changes, healthcare institutions are being tasked with handling a higher volume of patients, rising costs, and heightened performance pressures. Laboratories, in particular, are ...
ABBOTT PARK, Ill., March 5, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Regional Medical Laboratory, Inc. (RML) will use the company's most advanced technology, Alinity ci-series, to ...
ABBOTT PARK, Ill., June 14, 2017 — Abbott announced today that the Alinity hq analyzer for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer ...
* Abbott laboratories - secured U.S. FDA 510 clearance for its alinity ci-series instruments for clinical chemistry and immunoassay diagnostics Source text for Eikon: Further company coverage: Sign ...
How important are diagnostic tests in clinical decision making? Diagnostic tests are critical as up to 60 to 70% of critical clinical decisions are influenced by diagnostic test results. It's of huge ...
ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System. This new ...
According to the U.S. Centers for Disease Control (CDC), most sexually active adults will experience HPV infections; new test detects those HPV genotypes that could lead to cancer Abbott (ABT)'s new ...
ABBOTT PARK, Ill., June 14, 2017 — Abbott announced today that the Alinity hq analyzer for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback